Wednesday, July 15, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

Unvaccinated kids can stay in school after exposure if tested, CDC says

With a potential surge in COVID-19 cases in the coming weeks, the Biden administration pressed its new strategy to reduce the time unvaccinated children miss in school after a virus exposure.

Dr. Rochelle Walensky, director of the Centers for Disease Control and Prevention, said the “test to stay” strategy would increase testing of children and their close contacts after an exposure to someone who has tested positive for COVID-19 in order to prevent the child from having to isolate at home and miss time in class.

The new guideline allows unvaccinated children to remain in school after an exposure under certain circumstances, including undergoing multiple tests. For children to remain in school, two negative tests within a week after the exposure are required.

Source: USA Today

https://www.usatoday.com/story/news/health/2021/12/17/covid-vaccine-mandate-cases-health-care-workers/8933003002/

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Videos

Policy Shift in Peptide Regulation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

Clinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...

Read more

Join Our Newsletter!